Autism Spectrum Disorder Therapy in Maplewood, NJ

This is probably the most important paragraph on this page, and we’re leading with it so there’s no confusion down the road: we are a PMHNP practice providing psychiatric evaluation, medication management, and brief supportive therapy for autistic adolescents and adults. We do not provide Applied Behavior Analysis (ABA), speech and language therapy, occupational therapy, or social-skills training. Those interventions are delivered by specialized providers (BCBAs, speech-language pathologists, occupational therapists, trained social-skills groups). We coordinate with those providers, and we do not duplicate or replace them.

Care at Maplewood Mental Health Clinic can include:

• Psychiatric evaluation — diagnostic workup for co-occurring mental-health conditions; we can confirm a prior ASD diagnosis and use DSM-5-TR criteria but typically refer for formal autism diagnostic testing (ADOS-2, ADI-R) to licensed psychologists.
• Medication management for co-occurring conditions — anxiety, depression, ADHD, OCD, sleep disorders, agitation or irritability.
• Medications for autism-specific irritability — risperidone and aripiprazole carry FDA approval for irritability associated with autism in specific age ranges, with careful metabolic monitoring.
• Care coordination with your BCBA team, speech-language pathologist, occupational therapist, school IEP team, and primary-care physician.
• Adult autism psychiatric care — particularly important because most autism clinics are child-focused; adults often struggle to find psychiatric providers fluent in adult autism.

If what you’re looking for is ABA, social-skills training, or behavioral therapy for autism itself, we’re not the right provider — but we can help point you toward appropriate NJ-based options.

Co-occurring mental-health conditions are the rule rather than the exception in autism. Roughly 70% of autistic adolescents and adults have at least one co-occurring psychiatric condition; many have multiple. Treating those conditions often produces meaningful quality-of-life improvement that no amount of autism-specific intervention will produce, because the co-occurring conditions have their own distinct treatment pathways.

ADHD. Roughly 30–50% of autistic patients also meet criteria for ADHD¹. The combination is common enough that some researchers propose considering them as overlapping rather than separate conditions. Treatment follows ADHD pathways — stimulants (methylphenidate, amphetamine families) as first-line, non-stimulants (atomoxetine, guanfacine, viloxazine) as alternatives — with awareness that stimulants can sometimes increase anxiety or irritability in autistic patients, so starting at lower doses and titrating carefully is wise.

Anxiety. Generalized anxiety, social anxiety, specific phobias, panic, and separation anxiety all occur at elevated rates in autism. SSRIs are first-line pharmacotherapy. CBT adapted for autistic patients has evidence; we refer to therapists with autism-specific CBT training. Sensory sensitivities, predictability needs, and communication preferences shape how therapy is delivered.

Depression. Late-adolescent and adult autistic patients experience depression at substantially elevated rates. First-line treatment is SSRIs plus therapy; the considerations mirror depression treatment generally, with attention to the specific stressors autism produces (masking fatigue, social exclusion, employment barriers, inadequate support services).

OCD. OCD is common in autism, and the two can be confused. Core OCD obsessions and compulsions are ego-dystonic (they feel foreign and distressing); autistic routine preferences and special interests are ego-syntonic (they feel consistent with who the person is and are often valued). Both can coexist, and distinguishing them shapes the treatment plan. For OCD in autistic patients, the IOCDF framework applies — higher-dose SSRIs plus ERP delivered by a trained specialist.

Sleep disorders. Insomnia, delayed sleep phase, and non-24-hour sleep-wake patterns affect a substantial portion of autistic patients. We assess for contributing factors (anxiety, sensory environment, medication effects, sleep hygiene) and target the underlying contributor. Melatonin has good evidence in autism for sleep-onset insomnia and is often first-line. Mirtazapine is useful for insomnia-plus-anxiety. We use zolpidem and benzodiazepines cautiously; they are not first-line for chronic insomnia in autism.

Aggression, self-injury, and severe irritability. See the next section — this is where risperidone and aripiprazole come in.

Autism care almost always involves a team. Part of what we do is coordinate effectively with the team members delivering the non-psychiatric pieces.

BCBA and ABA team. With your consent, we share treatment updates, medication changes, and clinical observations with the BCBA team. They share behavior data and observed-response information with us. This bidirectional communication means medication decisions are informed by actual behavioral data, not just visit-day snapshots.

Speech-language pathologists. Communication support shapes the environment in which psychiatric care happens. For patients using AAC systems (picture exchange, speech-generating devices), we adapt visit format accordingly. For nonspeaking or minimally speaking patients, we work with the SLP and family to establish reliable communication patterns.

Occupational therapists. Sensory considerations matter for visit structure — lighting, sound level, seating, pacing. We defer to OT input on sensory accommodations the patient needs and build them into the visit format.

School IEP team.For adolescents still in school, we can provide documentation supporting IEP or 504 plan accommodations, school-based behavioral-health services, and medication-related adjustments to academic demands. We don’t attend IEP meetings routinely but provide written input when requested.

Primary care. Routine health maintenance, medical comorbidities (seizure disorders, GI issues common in autism, obesity management, cardiovascular risk), and overall care coordination. We share medication changes and any metabolic monitoring results; PCP shares physical health data that shapes psychiatric prescribing choices.

Genetics, neurology, and gastroenterology as indicated. For some autistic patients, genetic workup, neurological evaluation (particularly for suspected seizures), or GI evaluation is appropriate. We refer and coordinate.

Telehealth often works well for autistic patients. For patients with sensory sensitivities, the home environment is already set up to be sensory-appropriate — you know the lighting, the sound level, the seating that works for you, and you can adjust without explanation. The fluorescent lights, waiting-room hum, and unpredictable sensory input of a clinical office are removed from the equation.

Transportation is often a barrier for autistic patients and families — navigating transit, driving with executive-function challenges, the specific stress of unfamiliar routes. Telehealth removes that barrier. For adults with autism who live independently but find travel logistics burdensome, telehealth is often the difference between sustainable ongoing care and dropping out of treatment.

Some autistic patients specifically prefer in-person care because visual and nonverbal communication cues are richer in person. Others prefer the more contained, predictable format of video visits. We’re flexible; tell us what works.

For patients using AAC (augmentative and alternative communication) systems, telehealth sometimes requires adaptation — a second device for the AAC system, written-chat alongside video, or a support person present for technical assistance. We plan the setup at the first visit.

Neurodivergence-affirming care is a clinical stance, not a slogan. It means distinguishing clearly between traits of being autistic that are part of how you experience the world (preferences for routine, deep special interests, different social communication patterns, sensory sensitivities, stimming) and symptoms of distress or impairment that warrant treatment (severe anxiety, depression, OCD, sleep disruption, self-injury, unmanaged ADHD, severe irritability).

The traits don’t need to be treated as pathology. The distress does. Our work is to treat what’s causing suffering or functional impairment, not to make an autistic person less autistic.

Practically, this means: we don’t try to medicate away special interests or reduce stimming that isn’t harmful; we don’t frame autism itself as something to be fixed; we respect self-identification alongside formal diagnosis; we use identity-first language (“autistic person”) when patients prefer it and person-first language (“person with autism”) when patients prefer that — the patient’s preference governs. We acknowledge ongoing debates within the autism community about ABA specifically and hold space for patients and families who have mixed or negative experiences with it.

At the same time, neurodivergence-affirming care is not an excuse to undertreat co-occurring mental-health conditions. Severe anxiety, severe depression, OCD, and self-injurious behavior benefit from evidence-based treatment regardless of a patient’s autism status. Both things are true.

Teresa is a PMHNP-BC — board-certified Psychiatric Mental Health Nurse Practitioner — with 5 years of clinical experience across the major outpatient psychiatric conditions. Her scope in autism care is psychiatric evaluation, medication management for co-occurring conditions, medications for autism-specific irritability when indicated, brief supportive therapy integrated into visits, and active coordination with BCBA teams, speech-language pathologists, occupational therapists, school IEP teams, and primary-care clinicians.

We see patients ages 12 and older. For children under 12 with autism, we refer to pediatric mental health services. For adolescents and adults, we provide care directly. Visits typically run 30–45 minutes for follow-up; initial evaluation is 60–90 minutes. Follow-up cadence during medication titration is every 2–4 weeks; maintenance visits are every 1–3 months depending on stability and the specific medications in play.

Hybrid telehealth and in-person care is common. Adult patients on Schedule II stimulants for co-occurring ADHD follow current New Jersey rules (initial in-person evaluation, quarterly in-person follow-ups, routine visits via telehealth). For patients under 18 on stimulants, the pediatric exception with written parental consent allows full telehealth prescribing. All other prescribing — SSRIs, non-stimulants, risperidone/aripiprazole, melatonin, mirtazapine — can be prescribed via telehealth after an initial evaluation.